Policy & Regulation
Hemogenyx Pharmaceuticals signs development agreement with undisclosed global pharmaceutical company
15 May 2018 -

United Kingdom-based Hemogenyx Pharmaceuticals has signed a development agreement with an undisclosed global pharmaceutical company engaged in the research, development, manufacture and marketing of pharmaceutical products, it was reported yesterday.

According to the development agreement, Hemogenyx will receive on a cost-free basis, technical support, access to advanced methods of discovering, developing and engineering antibodies, and certain intellectual property, which is likely to assist the successful preclinical development of Hemogenyx's lead candidate bi-specific CDX antibodies. This will complement the firm's own development work presently being undertaken. The agreement stipulates certain confidential provisions, including, at this stage, the pharmaceutical company's identity. Under the Agreement, Hemogenyx will grant the global pharmaceutical company a research license for anything jointly developed under the agreement, and an option for an exclusive worldwide license to commercially exploit CDX antibodies or any variants that will be jointly developed under the agreement.

Hemogenyx CEO, Dr Vladislav Sandler, said, 'This agreement provides additional support for our development plans for CDX antibodies, and complements the work that we are already undertaking with our own resources. This close collaboration offers the potential for ongoing value-adding licensing arrangements with a major global pharmaceutical company with the benefit of their global reach and large-scale resources.'



Related Headlines